Search

Agios Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

33.39 -0.12

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

32.22

Max

33.83

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.6M

-101M

Pardavimai

24M

45M

Pelnas, tenkantis vienai akcijai

-1.69

Pelno marža

-225.06

Darbuotojai

539

EBITDA

-11M

-109M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+23.48% upside

Dividendai

By Acuity

Kitas uždarbis

2026-10-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-253M

1.9B

Ankstesnė atidarymo kaina

33.51

Ankstesnė uždarymo kaina

33.39

Naujienos nuotaikos

By Acuity

34%

66%

104 / 340 reitingas Healthcare

Agios Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-12 20:01; UTC

Agios Pharmaceuticals Inc shares are higher today amid unusually high trading volume. The stock has gained significantly since Tuesday's close.

2026-08-11 19:26; UTC

Agios Pharmaceuticals Inc shares are higher today, with no specific news driving the move. Market focus remains on upcoming U.S. inflation reports.

2026-08-10 21:01; UTC

Agios Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains below its 20-day moving average.

2026-08-06 19:32; UTC

Agios Pharmaceuticals shares are higher today, continuing an upward trend since Wednesday. The stock peaked earlier in the session before a slight pullback.

2026-08-05 19:56; UTC

News

Agios Pharmaceuticals is under investigation regarding its decision on tebapivat, contributing to lower trading activity today amid ongoing investor concerns.

2026-08-04 20:02; UTC

Agios Pharmaceuticals Inc shares are higher today amid broader market gains, supported by falling crude oil prices and comments on potential peace talks with Iran.

2026-08-03 20:06; UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

2026-07-31 22:51; UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

2026-07-30 20:08; UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

2026-07-29 20:51; UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

2026-07-28 20:02; UTC

News

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

2026-07-27 20:01; UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

2026-07-24 23:21; UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

2026-07-22 22:41; UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

2026-07-21 19:01; UTC

News
Event
Social Media

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.

Akcijų palyginimas

Kainos pokytis

Agios Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

23.48% į viršų

12 mėnesių prognozė

Vidutinis 41.33 USD  23.48%

Aukščiausias 55 USD

Žemiausias 31 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Agios Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

6

Pirkti

3

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

104 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat